Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novartis AG's Drug Afinitor Gets EU Nod For Breast Cancer-Reuters


Monday, 30 Jul 2012 04:17am EDT 

Reuters reported that Novartis AG's drug Afinitor, was approved by European regulators to treat women with a certain type of breast cancer. The drug is known as mTOR inhibitors to be approved for post menopausal women with advanced hormone receptor positive, HER2-negative breast cancer. American health regulators also backed the drug as a breast cancer treatment. Afinitor, also known as everolimus, is designed to be given in combination with another drug, Aromasin, to treat women whose cancer has recurred or progressed after treatment with two other therapies. 

Company Quote

79.6
-0.05 -0.06%
11 Jul 2014